Corlift

Vericiguat INN

Composition
Corlift 2.5 Tablet: Each film coated tablet contains Vericiguat INN 2.5 mg.
Corlift 5 Tablet: Each film coated tablet contains Vericiguat INN 5 mg.
Corlift 10 Tablet: Each film coated tablet contains Vericiguat INN 10 mg.

Description
Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, Vericiguat augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.

Indication
Vericiguat is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Dosage and administration
The recommended starting dose of Vericiguat is 2.5 mg orally once daily with food. Double the dose of Vericiguat approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablets, Vericiguat may be crushed and mixed with water immediately before administration.
Pediatric Use: Safety and effectiveness of Vericiguat have not been established in pediatric patients.
Geriatric Use: No dosage adjustment of Vericiguat is required in geriatric patients.
Renal impairment: No dosage adjustment of Vericiguat is recommended in patients with estimated glomerular filtration rate of eGFR ≥15 mL/min/1.73m² who are not on dialysis. Vericiguat has not been studied in patients with eGFR ≤15 mL/min/1.73m².
Hepatic Impairment: No dosage adjustment of Vericiguat is recommended in patients with mild or moderate hepatic impairment. Vericiguat has not been studied in patients with severe hepatic impairment.

Use in pregnancy and lactation
Vericiguat may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy. Vericiguat or its metabolites may be present in human milk.
So, breastfeeding is not recommended during pregnancy.

Adverse effects
Most common adverse reactions reported in ≥5% are hypotension and anemia.

BLACK BOX WARNING: EMBRYO-FETAL TOXICITY
- Do not administer Corlift to a pregnant female because it may cause fetal harm.
- Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment.

Warnings and precautions
Embryo-Fetal Toxicity: Based on data from animal reproduction studies, vericiguat may cause fetal harm when administered to a pregnant woman. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with vericiguat and for at least one month after the final dose.

Contraindications
Vericiguat is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators. Vericiguat is contraindicated in pregnancy.

Drug interactions
Vericiguat is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators. Concomitant use of Vericiguat with PDE-5 inhibitors is not recommended because of the potential for hypotension. No clinically significant differences on Vericiguat pharmacokinetics were observed with co-administration of mefenamic acid, ketoconazole, rifampin, digoxin, warfarin, aspirin, sildenafil, or the combination of sacubitril/valsartan in healthy subjects. No clinically significant differences on Vericiguat pharmacokinetics were predicted with coadministration of atazanavir.

Overdosage
Limited data are available with regard to overdosage in human patients treated with Vericiguat. Vericiguat is generally well tolerated. In the event of an overdose, hypotension may result. Symptomatic treatment should be provided. Vericiguat is unlikely to be removed by hemodialysis because of high protein binding.

Storage
Do not store above 25° C. Protect from light. Keep out of reach of children.

Packaging
Corlift 2.5 tablet: Each box contains 3×10's tablets in blister pack.
Corlift 5 tablet: Each box contains 2×10's tablets in blister pack.
Corlift 10 tablet: Each box contains 1×10's tablets in blister pack.

Manufactured by
ZISKA PHARMA
Ziska Pharmaceuticals Ltd.
Kaliakoir, Gazipur, Bangladesh

P-3060

Version: 00